Compare Amylx Pharmaceuticals Inc (AMLX) vs Tidewater Inc (TDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Tidewater Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.12 (market cap $1.98B), while Tidewater Inc trades at $73.89 (market cap $3.65B). The key difference: Tidewater Inc is the larger of the two by market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Tidewater Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | TDW | |
|---|---|---|
Market Cap | $1.98B | $3.65B |
Sector | Health | Utilities |
52-Week High | $18.70 | $91.12 |
52-Week Low | $7.64 | $46.32 |
Enterprise Value | $1.70B | $3.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Tidewater (TDW) trades at $73.37, up 3.84% with bullish technical signals from moving averages. The company maintains strong profitability with 22.16% net income margin and 24.03% ROE, though recent Q1 2026 earnings missed estimates. Valuation appears reasonable with P/E of 12.37 and EV/EBITDA of 9.15. Recent news includes FTAI Infrastructure's acquisition of Tidewater Logistics and mixed analyst sentiment.
The outlook remains cautiously optimistic given strong fundamentals but tempered by recent earnings misses. Investment opportunity lies in reasonable valuation and sector positioning, while risks include execution challenges and energy market volatility. Analyst consensus leans neutral with 61.54% hold ratings, suggesting balanced risk-reward profile.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
